BIOCOMBiotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several new formats are expected to enter the market in the next few years, promising to significantly reduce the side effects of CAR-Ts, bispecific antibodies, ADCs, etc. and improve their efficacy.
Memorial Sloan Kettering Cancer CentreUS spin-out of German MPI for molecular genetics, Harbinger Health Inc, has started a collaboration with Memorial Sloan Kettering Cancer Centre to turboboost recruiting for its Core-HH study. The study aims to validate a blood test that predicts tumour developement in cancer stage I.
Novo NordiskNovo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
ProBioGenThe Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccines.
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.
© Niclas Jessen Studio/Bracco Imaging SpARadiopharmaceuticals specialist Blue Earth Therapeutics Ltd will use a U$76.5m Series A financing to finance Phase II development of its targeted prostate cancer radiopharmaceuticals Lutetium (177-Lu) rhPSMA-10.1 and Actinium (225-Ac) rhPSMA-10.1.
EniferAs the first Nordic company seeking Novel Food approval for a mycoprotein ingredient, Finnish Enifer has filed a authorisation application for it brand PEKILO to the EU food watchdog EFSA.
Knowledge Seeker - wikipedia.orgDigital pathology specialist AIgnostics GmbH has topped up its cash position to US$55m with a US$34m Series B financing. The money will be used to optimise the company’s RudolfV Foundation Model and to develop and offer new services for target and biomarker identification selection, particularly in the US pharma market.
Resalis/VimeoItalian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through Phase II proof-of-concept.
UCB SABelgian UCB SA and British Cancer UK have started a second clinical study within their multi-year partnership to evaluate the safety and tolerable dose of UCB4594 in patients with advanced cancers.